IMGN-779 represents the significant medicinal candidate in acute leukemia arena. This first-in-class bare immunoglobulin selectively recognizes CD33, an protein present in a significant portion of acute myeloid https://www.targetmol.com/compound/anti_cd33_antibody__imgn_779_naked_antibody_